ERIS LIFESCIENCES SHARE PRICE

ERIS Lifesciences Ltd. is an Indian company that manufactures and markets pharmaceutical products. Its manufacturing plant is located in Guwahati, Assam. It was incorporated in 2007, with its headquarters in Ahmedabad, Gujarat. The company’s total income for the September 2022 quarter was Rs 465.88 crore, up 16.04% against Rs 401.32 crore for the June 2022 quarter. On 25 October 2022, ERIS Lifesciences Ltd.’s market capitalisation stood at Rs 9,751 crore.

The company is listed on the Bombay Stock Exchange with the code 540596 and on the National Stock Exchange with the code ERIS.

ERIS Lifesciences Ltd. mainly focuses on cardiology, endocrinology, ENT, paediatrics, gynaecology, gastroenterology, and orthopaedics segments. It offers world-class products across these therapy segments. The company’s brands include Tendia, Tayo, Crevast, Cyblex, Glimisave, Metital, Ginkocer, and Olmin.

On 30 September 2022, the company’s shareholding pattern showed a 52.29% promoter stake, a 15.39% FII stake, a 10.69% DII stake, and a 21.63% public stake. The leading promoter is Mr Amit Indubhushan Bakshi, the company’s founder, with a 40.27% share. During the September 2022 quarter, promoter holdings decreased from 52.30% to 52.29%, mutual fund holdings increased from 10.36% to 10.38%, and FII holdings increased from 15.35% to 15.39%.

Mr Amit Indubhushan Bakshi is the company’s chairperson and managing director. The other team members include Mr Krishnakumar Vaidyanathan, Mr Kaushal Shah, Mr Rajeev Dalal, Mr Sachin Shah, Mr Inderjeet Singh Negi, Mr Prashant Gupta, Mr Milind Talegaonkar, Mr Vasudevan Sujesh, and Ms Kalpana Unadkat. Its auditors are Deloitte Haskins & Sells LLP. On 30 September 2022, the company had a total of 13.60 crore shares outstanding.

On 25 October 2022, the company’s share price closed at Rs 712.10 on BSE and Rs 717.10 on NSE. The 52-week high for ERIS Lifesciences Ltd.’s shares was Rs 835, and its 52-week low was Rs 600.30. Its six-month investor return was 2.42%, and the one-year return was -12.14%.

The company’s peers include Dr Reddys Laboratories Ltd., Cipla Ltd., Sun Pharmaceuticals Industries Ltd., and Divis Laboratories Ltd.

As of September 2022, Franklin India Smaller Companies Fund had a 1.77% stake in the company. Aditya Birla SL Equity Hybrid Fund and L&T Midcap Fund had 1.58% and 1.29% stakes, respectively.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

ERIS Lifesciences share price as on 08 Jul 2025 is Rs. 1734. Over the past 6 months, the ERIS Lifesciences share price has increased by 33.66% and in the last one year, it has increased by 68.33%. The 52-week low for ERIS Lifesciences share price was Rs. 1009 and 52-week high was Rs. 1910.

ERIS Lifesciences Ltd. is an Indian company that manufactures and markets pharmaceutical products. Its manufacturing plant is located in Guwahati, Assam. It was incorporated in 2007, with its headquarters in Ahmedabad, Gujarat. The company’s total income for the September 2022 quarter was Rs 465.88 crore, up 16.04% against Rs 401.32 crore for the June 2022 quarter. On 25 October 2022, ERIS Lifesciences Ltd.’s market capitalisation stood at Rs 9,751 crore.

The company is listed on the Bombay Stock Exchange with the code 540596 and on the National Stock Exchange with the code ERIS.

ERIS Lifesciences Ltd. mainly focuses on cardiology, endocrinology, ENT, paediatrics, gynaecology, gastroenterology, and orthopaedics segments. It offers world-class products across these therapy segments. The company’s brands include Tendia, Tayo, Crevast, Cyblex, Glimisave, Metital, Ginkocer, and Olmin.

On 30 September 2022, the company’s shareholding pattern showed a 52.29% promoter stake, a 15.39% FII stake, a 10.69% DII stake, and a 21.63% public stake. The leading promoter is Mr Amit Indubhushan Bakshi, the company’s founder, with a 40.27% share. During the September 2022 quarter, promoter holdings decreased from 52.30% to 52.29%, mutual fund holdings increased from 10.36% to 10.38%, and FII holdings increased from 15.35% to 15.39%.

Mr Amit Indubhushan Bakshi is the company’s chairperson and managing director. The other team members include Mr Krishnakumar Vaidyanathan, Mr Kaushal Shah, Mr Rajeev Dalal, Mr Sachin Shah, Mr Inderjeet Singh Negi, Mr Prashant Gupta, Mr Milind Talegaonkar, Mr Vasudevan Sujesh, and Ms Kalpana Unadkat. Its auditors are Deloitte Haskins & Sells LLP. On 30 September 2022, the company had a total of 13.60 crore shares outstanding.

On 25 October 2022, the company’s share price closed at Rs 712.10 on BSE and Rs 717.10 on NSE. The 52-week high for ERIS Lifesciences Ltd.’s shares was Rs 835, and its 52-week low was Rs 600.30. Its six-month investor return was 2.42%, and the one-year return was -12.14%.

The company’s peers include Dr Reddys Laboratories Ltd., Cipla Ltd., Sun Pharmaceuticals Industries Ltd., and Divis Laboratories Ltd.

As of September 2022, Franklin India Smaller Companies Fund had a 1.77% stake in the company. Aditya Birla SL Equity Hybrid Fund and L&T Midcap Fund had 1.58% and 1.29% stakes, respectively.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

ERIS Lifesciences share price as on 08 Jul 2025 is Rs. 1734. Over the past 6 months, the ERIS Lifesciences share price has increased by 33.66% and in the last one year, it has increased by 68.33%. The 52-week low for ERIS Lifesciences share price was Rs. 1009 and 52-week high was Rs. 1910.